XTX Topco »

Inhibikase Therapeutics shares owned by XTX Topco

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by XTX Topco from 13F filings

Historical chart of XTX Topco investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by XTX Topco consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by XTX Topco

Quarter filed Position value Share count Share price at filing
2025-12-31 $42k 20k 2.05

More positions owned by XTX Topco

Procter & Gamble Company (PG)
JPMorgan Chase & Co. (JPM)
NVIDIA Corporation (NVDA)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Apple (AAPL)
Cme (CME)
Kroger (KR)
At&t (T)
Vanguard Index Fds Total Stk Mkt (VTI)
Metropcs Communications (TMUS)
First Ctzns Bancshares Inc D Cl A (FCNCA)
S&p Global (SPGI)
Albertsons Cos Common Stock (ACI)
O'reilly Automotive (ORLY)
Owl Rock Capital Corporation (OBDC)

View all positions for XTX Topco

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Fairmount Funds Management
ADAR1 Capital Management
Siren
Perceptive Advisors
Commodore Capital
Vanguard Group
Nantahala Capital Management
Saturn V Capital Management
BlackRock
Blackstone Group
Stonepine Capital Management
Integral Health Asset Management
Ameriprise Financial

View all funds holding Inhibikase Therapeutics